XOMA Royalty Corp. (XOMA) P/E Ratio History
UndervaluedTrading at 28.7x vs 5Y avg 67.5x · 38th percentile · Below historical baseline · Data 2009–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, XOMA Royalty Corp. (XOMA) trades at a price-to-earnings ratio of 28.7x, with a stock price of $41.89 and trailing twelve-month earnings per share of $1.81.
The current P/E is 58% below its 5-year average of 67.5x. Over the past five years, XOMA's P/E has ranged from a low of 7.8x to a high of 353.6x, placing the current valuation at the 38th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, XOMA trades at a 30% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 2.15 (P/E divided by 188% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, XOMA trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XOMA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
XOMA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
XOMA P/E vs Peers
Royalty and IP Monetization Vehicles peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $23B | 29.4 | 4.17 | -6% | |
| $6B | 17.9 | 0.47Best | +8% | |
| $143B | 18.5 | - | -4% | |
| $281B | 15.6Lowest | 0.74 | +8% | |
| $383B | 91.4 | - | -1% | |
| $110B | 15.7 | - | +178%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
XOMA Historical P/E Data (2009–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $31.37 | $1.57 | 20.0x | -70% |
| FY2025 Q4 | Dec 31 2025 | $26.59 | $1.47 | 18.1x | -73% |
| FY2025 Q3 | - | $38.54 | $0.76 | 50.9x | -25% |
| FY2022 Q3 | Sep 30 2022 | $17.91 | $0.57 | 31.4x | -53% |
| FY2022 Q2 | - | $22.28 | $0.53 | 42.0x | -38% |
| FY2022 Q1 | - | $27.98 | $0.86 | 32.5x | -52% |
| FY2021 Q4 | Dec 31 2021 | $20.85 | $0.42 | 49.6x | -26% |
| FY2021 Q3 | - | $24.75 | $0.07 | 353.6x | +424% |
| FY2021 Q2 | Jun 30 2021 | $34.00 | $0.36 | 93.8x | +39% |
| FY2021 Q1 | Mar 31 2021 | $40.81 | $0.23 | 175.7x | +160% |
| FY2020 Q4 | - | $44.13 | $0.40 | 109.7x | +62% |
| FY2018 Q2 | Jun 30 2018 | $20.88 | $2.33 | 9.0x | -87% |
| FY2018 Q1 | Mar 31 2018 | $20.23 | $2.60 | 7.8x | -88% |
| FY2017 Q4 | Dec 31 2017 | $35.60 | $1.50 | 23.8x | -65% |
| FY2016 Q2 | - | $11.00 | $0.24 | 46.0x | -32% |
| FY2009 Q3 | Sep 30 2009 | $243.00 | $14.86 | 16.4x | -76% |
Average P/E for displayed period: 67.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
XOMA — Frequently Asked Questions
Quick answers to the most common questions about buying XOMA stock.
What is XOMA's P/E ratio?
XOMA Royalty Corp. (XOMA) trailing twelve-month P/E ratio is 28.7x, based on TTM diluted EPS of $1.81. The 5-year average P/E is 67.5x and the historical range spans 7.8x to 353.6x.
Is XOMA stock overvalued or undervalued?
XOMA trades at 28.7x P/E, below its 5-year average of 67.5x. At the 38th percentile of its historical range (7.8x–353.6x), the stock is priced at a discount to its own history.
Is XOMA stock expensive?
No, XOMA is not expensive on a historical basis. The current P/E of 28.7x is below the 5-year average of 67.5x and sits at the 38th percentile of its valuation range.
What is XOMA's historical P/E range?
Over the past 5 years, XOMA's P/E ratio has ranged from 7.8x to 353.6x, with a median of 42.0x and an average of 67.5x. The current P/E of 28.7x places the stock at the 38th percentile of this range. Full historical data spans 2009–2026.
How does XOMA's P/E compare to the S&P 500?
XOMA trades at 28.7x P/E versus the S&P 500 median of 24.4x. The 18% premium to the market typically reflects higher expected earnings growth or quality.
How does XOMA's valuation compare to Healthcare peers?
XOMA Royalty Corp. P/E of 28.7x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is XOMA's PEG ratio?
XOMA PEG ratio is 2.15, based on a P/E of 28.7x and EPS growth of 188.5%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is XOMA's earnings yield?
XOMA earnings yield is 3.49%, the inverse of its 28.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.